HOME >> BIOLOGY >> NEWS
Three inferior prefrontal regions of the brain found receptive to somatosensory stimuli

(November 19, 2002) - Bethesda, MD -- We know quite a bit about the orbitofrontal cortex (OFC). It is part of the frontal lobe that lies superior to the orbit of the eyes. This area of the brain plays an important role in emotional behavior, receives direct inputs from the dorsomedial thalamus, temporal cortex, ventral tegmental area, olfactory system, and the amygdala (illustration). Its outputs go to several brain regions, including the cingulate cortex, hippocampal formation, temporal cortex, lateral hypothalamus, and amygdala. Finally, it communicates with other regions of the frontal cortex. Thus its inputs provide it with information about what is happening in the environment and what plans are being made by the rest of the frontal lobes. Its outputs permit it to affect a variety of behaviors and physiological responses, including emotional responses organized by the amygdala.

However, there is still much that we do not know about this important part of the brain. Research has shown that three inferior prefrontal regions of the monkey's brain (OFC, ventral area of the principal sulcus, and the anterior frontal operculum) all receive somatosensory stimuli (indirect sensations to the body as opposed to specific stimuli such as light). Now a groundbreaking research effort has incorporated two studies, combining positron emission tomography with neutral tactile (touch) stimulation to determine if these same regions in the human brain respond accordingly.

The authors of "Somatosensory Processing in the Human Inferior Prefrontal Cortex" are Matthew C. Hagen and Jose V. Pardo, both from the Veterans Affairs Medical Center and the University of Minnesota Medical School, Minneapolis, MN; and David H. Zald and Tricia A. Thornton, both from Vanderbilt University, Nashville, TN. Their findings are published in the Journal of Neurophysiology, a publication of the American Physiological Society (APS).

S T U D Y 1

Met
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
19-Nov-2002


Page: 1 2 3 4 5

Related biology news :

1. Three new South American fish identified
2. Three personal ads for physics
3. Three molecular-targeted compounds show promise against cancers
4. Three genes linked to psoriasis susceptibility identified on chromosome 17
5. Three Pacific Northwest National Laboratory inventions win R&D 100 Awards
6. Three Gorges Dam is an opportunity for ecoscience
7. Three tourist experiences named best worldwide for environmental, social responsibility
8. Three dimensional structure of a protein transport machine
9. Three studies released this week shed new light on eating nuts for good health
10. Three nations agree to share ice core thatmay yield clues about nature of Lake Vostok
11. Three-D images shed light on first steps of RNA synthesis

Post Your Comments:
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: